LifeStance Health Group, Inc. shares surged 14.43% in pre-market trading following the release of its fourth quarter and full-year 2025 financial results, which exceeded analyst expectations and were accompanied by the announcement of a significant capital return program.

The mental healthcare provider reported Q4 revenue of $382.2 million, a 17% year-over-year increase that beat the IBES estimate of $376.3 million. Adjusted EBITDA for the quarter was $48.8 million, significantly surpassing the $40.3 million estimate, driven by higher visit volumes and improved operating leverage. The company also reported net income of $11.7 million for the quarter.

Further bolstering investor sentiment, LifeStance's Board of Directors approved a $100 million share repurchase program, reflecting confidence in the company's strong cash generation and healthy balance sheet. The company also provided optimistic guidance for 2026, expecting full-year revenue in the range of $1.615 billion to $1.655 billion and Adjusted EBITDA of $185 million to $205 million.